| Literature DB >> 29871625 |
Aleksandra E Zgierska1, Regina M Vidaver2, Paul Smith2, Mary W Ales3, Kate Nisbet3, Deanne Boss2, Wen-Jan Tuan2, David L Hahn2.
Abstract
BACKGROUND: Systematic implementation of guidelines for opioid therapy management in chronic non-cancer pain can reduce opioid-related harms. However, implementation of guideline-recommended practices in routine care is subpar. The goal of this quality improvement (QI) project is to assess whether a clinic-tailored QI intervention improves the implementation of a health system-wide, guideline-driven policy on opioid prescribing in primary care. This manuscript describes the protocol for this QI project.Entities:
Keywords: Access and evaluation; Chronic pain; Healthcare quality; Healthcare systems; Opioid analgesics; Quality improvement
Mesh:
Substances:
Year: 2018 PMID: 29871625 PMCID: PMC5989454 DOI: 10.1186/s12913-018-3227-2
Source DB: PubMed Journal: BMC Health Serv Res ISSN: 1472-6963 Impact factor: 2.655
Outline of the recommendations of the health system’s opioid management policy
| Item | Summary of the Policy-recommended Components |
|---|---|
| Recommended components of opioid therapy management | |
| Problem List | 1. Document diagnosis of chronic pain and source of pain |
| 2. Document information related to relevant prescribed medications: | |
| a. Details of opioid prescription, with allowed quantity per given time period | |
| 3. PDMP review: date of last review, finding summary, e.g., consistent or inconsistent with prescription record | |
| 4. Document care plan | |
| 5. Add comments helpful to other providers, e.g., those covering in your absence | |
| 6. Update at least annually and when any changes occur | |
| Care Plan Components | 1. Treatment goals: pain severity (BPI), function (BPI/other) |
| 2. Treatment plan (medications, exercise, physical or occupational therapy, mental health related therapies, CAM therapies, specialty consults) | |
| 3. Contingency plan for care outside PCP office | |
| 4. Update at least annually and when any changes to care plan | |
| Treatment | 1. Serves as informed consent to long-term opioid therapy |
| 2. Scan new or updated signed treatment agreement into the EHR | |
| 3. Update treatment agreement annually and when any changes to care plan | |
| 4. Deactivate treatment agreement after opioids are no longer prescribed | |
| Urine Drug Testing | 1. Complete urine drug testing annually or more frequently as needed |
| 2. Perform confirmatory testing for unexpected results of a screening test | |
| 3. Document findings | |
| Prescription Refills | 1. Prescription for controlled substances should be filled at one agreed upon pharmacy, which is noted in the treatment agreement |
| 2. Prescriptions for Schedule II medications can be mailed to pharmacy only | |
| 3. Patient may sign a release form to designate up to 2 appointees who can pick up prescriptions for Schedule II medications with photo ID | |
| PDMP | 1. Document findings of the PDMP database review at least annually. |
| Approach to treatment agreement violation | |
| Minor Infractions | 1. Patient should be contacted by prescribing provider; discussion documented |
| 2. Reassess and update care plan and treatment agreement as needed | |
| Major Infractions | Follow minor infraction steps above; in addition: |
| 1. If opioid therapy is discontinued, provide, when appropriate: | |
| 2. Document reason for the discontinuation of opioid therapy | |
| 3. Deactivate treatment agreement when opioid treatment is completed | |
| 4. Communicate with other treating clinicians | |
| 5. Contact Patient Relations; discuss placing a flag, if needed, in medical record by the Department of Pharmacy | |
| 6. Continue non-opioid treatment | |
| 7. If all care is planned to be terminated, discuss “No further service” with Patient Relations | |
| Suspected Misuse or Use Disorder | 1. Consider referring to addiction medicine specialist |
| 2. If safe, continue modified or current opioid therapy until plan is in place with addiction specialist | |
| 3. Consider following the steps as for major violation of the treatment agreement | |
BPI Brief Pain Inventory, CAM Complementary and Alternative Medicine, EHR Electronic Health Record, PCP Primary Care Provider, PDMP Prescription Drug Monitoring Program
The intervention for augmenting routine health system-based implementation of opioid policy recommendations in primary care
| QI Intervention Component | Description |
|---|---|
| Academic Detailing | A single on-site educational meeting between a content expert (project team member) and the clinicians and staff from the enrolled clinic wishing to improve the quality of care for their opioid-treated patients. |
| Two Online Educational Modules, delivered via email: | Brief, straightforward, and easily accessible educational tools delivered via the web or mobile devices. A set of 20–21 multiple-choice questions with instant feedback allows learners to assess and validate their current knowledge of the targeted content, which is presented in the context of a given health system setting. These modules were developed by the project team members, content area experts, and reviewed by the health system and external experts (content can be made available upon request). |
| Practice Facilitation | An evidence-based method of assisting clinical practices in changing and optimizing the process of care. External facilitators (project team members) assist practices in implementing their prioritized goals and changing practice workflow, typically using the Plan, Do, Study, Act cycle model, ([ |
| Two Patient Education Modules: | Brief, online educational tools for patients, professionally developed by Emmi Solutions, LLC ( |
Measures to evaluate the implementation of guideline and health system’s opioid management policy recommendations
| Evaluation Component | Clinic-Level Measures |
|---|---|
| Clinically-Relevant Outcomes | |
| EHR-based Measures (aggregate clinic-level data) | |
| Treatment Agreement | Percent of eligible patientsa with signed treatment agreement in the past 12 months. |
| Urine Drug Testing | Percent of eligible patientsa with the health system-recommended urine drug testing completed in the past 12 months. |
| Opioid Therapy Risk Assessment | Percent of eligible patientsa with documented screening using the health system-recommended D.I.R.E. opioid misuse risk tool. |
| Depression Screening | Percent of eligible patientsa with documented screening using the health system-recommended PHQ-2 or − 9 depression screening tool. |
| Co-prescription of Opioids and Benzodiazepinesb | Percent of eligible patientsa with presence of active prescriptions for both opioids and benzodiazepines. |
| PDMP Check | Percent of eligible patientsa with documented PDMP database check in the past 12 months. |
| Process Measures (aggregate clinic-level data) | |
| Clinic Team Surveys | Pre- and post-participation surveys will elicit: |
| Clinic Team Member Participation in the Intervention Components | Percent of clinicians and clinical staff per clinic who: |
| Data from Practice Facilitators | Practice facilitator notes and experiences will enable identification of themes relevant to the implementation of the opioid policy (barriers and facilitators). |
D.I.R.E Diagnosis, Intractability, Risk, Efficacy assessment tool, QI Quality Improvement, PDMP Prescription Drug Monitoring Program, PHQ Patient Health Questionnaire
aTarget population: health system’s primary care adult (18 years old or older) patients treated with long-term opioids for chronic non-cancer pain. To be included in the analysis, patients must have met the following criteria: age ≥ 18 years old; active patient status (seen in the past 3 years) in the health system’s January 2016 panel data; have a primary care provider at the health system’s general internal medicine or family medicine clinics; do not have a diagnosis of malignant neoplasm (except non-melanoma skin cancer) or hospice status; and meet at least one of the two health system’s “opioid registry” criteria: Criterion 1: have at least one opioid prescription issued in the prior 45 days AND at least three opioid prescriptions issued in the prior 4 months; Criterion 2: have at least one opioid prescription issued in the prior 45 days, AND chronic pain diagnosis listed, AND a controlled substance agreement
bThis element, although included in the opioid prescribing guidelines, was not a part of the health system’s policy on opioid therapy management